Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 24/03/2021

    Liver cancer: which patients benefit from immunotherapy?

    Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
  • Press release - 15/03/2021

    How novel pathogens may cause the development of colorectal cancer

    Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote cancer development in the long term.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-novel-pathogens-may-cause-development-colorectal-cancer
  • Press release - 01/02/2021

    Targeting a rapid market breakthrough for new vaccine production method

    In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
  • Press release - 03/12/2020

    HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

    New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-erreicht-meilenstein-mit-dem-nachweis-von-sicherheit-und-wirksamkeit-der-mkk4-inhibition-im-model-fuer-fortgeschritt
  • KyooBe Tech GmbH - 08/10/2020 Scheme of the patented pump and roll system (LEEI technology).

    Next generation vaccine production

    For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
  • Organ failure due to fatty liver - 24/09/2020 AdobeStock_9729015_SciePro_Leber_Mensch.jpg

    HepaRegeniX develops an active substance for liver regeneration

    When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
  • Press release - 13/05/2020

    Corona antibody tests from Reutlingen

    The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/corona-antikoerpertests-aus-reutlingen
  • Article - 11/06/2019 ZurHausen.jpg

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Cancer immunotherapy - 06/09/2018 Schematic showing the so-called breakthrough event as well as the expansion and invasion stages of cells during carcinogenesis.

    The immunogenicity of tumours and the development of new cancer medicines

    Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
  • Dossier - 28/08/2018 Woman wearing a white lab coat in a laboratory looking at a tube she is holding in her hand.

    With molecular diagnostics to biomarker-based personalised therapy

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
  • Press release - 04/01/2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
  • Transregional research cooperation - 11/10/2017 Schematic representation of liver and gall bladder. Hepatitis C viruses are depicted in the background as round orange particles with white surface proteins. Some HC viruses are highlighted in the top left-hand corner of the image.

    New research consortium to develop new liver cancer treatments

    The causes, signs and symptoms of liver cancer are extremely complex. Investigating them requires the collaboration of many experts across university and regional boundaries. A new transregional research group is now studying the complex overall mechanisms at the cellular, genetic and molecular level in order to develop new concepts and drugs for treating liver and bile duct cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-research-consortium-to-develop-new-liver-cancer-treatments
  • Article - 12/09/2016 Photo of the building housing the Department of Internal Medicine in Tübingen.

    New target for the therapy of hepatocellular carcinoma discovered

    Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
  • Article - 18/08/2016 HCV_particles_EM.jpg

    Chronic viral infections of the liver

    Hepatitis B and hepatitis C are two of the most common infectious diseases in the world. They often take a chronic course and carry a high risk of progressing to cirrhosis and hepatocellular carcinoma. A new transregional collaborative research centre involving scientists from Heidelberg and Freiburg is looking into how hepatitis B and hepatitis C viruses, which have different symptoms and treatments, are able to evade the immune system and allow…

    https://www.gesundheitsindustrie-bw.de/en/article/news/chronic-viral-infections-of-the-liver
  • Article - 30/06/2016 Fettfaerbung_in_der_Leber_HZ_Mchn.jpg

    Why fasting is good for health

    A protein in the nucleus of liver cells is produced in greater quantities when we go hungry; it limits fatty acid uptake and adjusts the metabolism in the liver. However in people with metabolic disorders, the abnormal expression of this protein (GADD45β), which was previously only known to be involved in the regulation of cell division and DNA repair, leads to a dysregulated fat and sugar metabolism. Scientists from the DKFZ and Helmholtz…

    https://www.gesundheitsindustrie-bw.de/en/article/news/why-fasting-is-good-for-health
  • Article - 02/05/2016 Schematic showing immune cells recognise a hepatitis C virus.

    Hepatitis C: a new starting point for vaccine development

    With approximately 150,000 infected people in Germany, hepatitis C is a common disease for which therapies, but no vaccine, are available. Dr. Tobias Böttler from the Freiburg University Medical Center and his team are exploring the body’s immune response to the hepatitis C virus (HCV) and have found valuable information that could be used for vaccine development.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hepatitis-c-a-new-starting-point-for-vaccine-development
  • Article - 20/07/2015 23437_de.jpg

    Liver cell carcinoma: reducing tumour burden – increasing life expectancy

    Liver cell carcinoma or hepatocellular carcinoma (HCC) is one of the most malignant human cancers. The disease arises from chronic damage to the liver, usually caused by virus- or alcohol-related liver cirrhoses. Liver tumours are considered difficult to treat, but there is evidence that they actually trigger an immune response in the body. Prof. Dr. Robert Thimme from Freiburg University Medical Centre is seeking to understand this effect and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/liver-cell-carcinoma-reducing-tumour-burden-increasing-life-expectancy
  • Article - 16/03/2015 Microscopic image of liver tissue. The area in the centre of the image has an intense yellow-red colour.<br />

    The critical balance between liver fibrosis and liver regeneration

    When the liver has been damaged, a receptor protein of the hepatic stellate cells called endosialin controls the balance between liver repair and scar formation. A team of researchers from Heidelberg and Mannheim has shown that endosialin is a positive regulator of fibrogenesis and a negative regulator of hepatocyte proliferation. Endosialin therefore seems to be a promising therapeutic drug target in non-neoplastic settings.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-critical-balance-between-liver-fibrosis-and-liver-regeneration
  • Dossier - 09/03/2015 22868_de.jpg

    Advances in the study and treatment of liver diseases

    Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively. Fewer advances…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/advances-in-the-study-and-treatment-of-liver-diseases
  • Article - 22/12/2014 22598_de.jpg

    Fighting hepatitis viruses with their own weapons

    Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…

    https://www.gesundheitsindustrie-bw.de/en/article/news/fighting-hepatitis-viruses-with-their-own-weapons
  • Article - 20/10/2014 22216_de.jpg

    Michael Schindler: HI virus and host interactions

    Prof. Dr. Michael Schindler explores the interaction between viruses and their human host cells on the molecular level. His specific interest is HI virus infections and the mechanisms the virus uses to attack the human immune system. Schindler’s eventual aim is to identify a new target for the therapy of HIV infections. In April 2014, Schindler was appointed head of the Department of Molecular Virology of Human Infectious Diseases at the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/michael-schindler-hi-virus-and-host-interactions
  • Dossier - 28/04/2014 Researcher sitting in front of two screens, visualising a protein on the screen using a specific software.<br />

    Data mining: new opportunities for medicine and public health

    Research and healthcare activities produce huge quantities of data that need to be presented in an understandable structure. This requires computer-assisted extraction of relevant data and the use of statistical methods. This process, known as data mining, enables the discovery of patterns in large data sets. Data mining methods are of particular importance in fields that use high-throughput methods, visualisation methods and telemedical…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/data-mining-new-opportunities-for-medicine-and-public-health
  • Dossier - 02/12/2013

    RNA interference: confidence is returning

    The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which the two Americans Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/rna-interference-confidence-is-returning
  • Article - 17/12/2012 18923_de.jpg

    Medicyte GmbH – gold standard for human cells

    Medicyte GmbH is a life sciences company located in the city of Heidelberg. It focuses primarily on the production of quasi-primary human cells of the highest quality and in virtually unlimited quantity. MediCyte’s goal is to establish its proprietary cell proliferation technologies as gold standard for the use of human cells and cell products in research, development and cell therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicyte-gmbh-gold-standard-for-human-cells
  • Article - 03/09/2012 12208_de.jpg

    Systems biology and hepatitis C research

    The international research project SysPatho aims to advance the understanding of HCV (hepatitis C virus) infections using systems biology approaches. The goal of the project coordinated by Universität Heidelberg is to develop new mathematical and computational methods to reconstruct HCV-infected hepatocytes, which can be used to identify new drug targets and help treat this dangerous disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/systems-biology-and-hepatitis-c-research

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search